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a b s t r a c t
Postinfarct VSD (PIVSD) carries a grim prognosis. The mainstay of management has been
surgical repair. The advent of septal occluder devices has offered an attractive alternative to
surgical repair. Most PIVSD have serpiginous tracts with necrotic tissue, which makes
assessing the defect challenging. 3D computer printing has become useful in preprocedure
planning of complex surgical procedures in multiple subspecialties.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Postinfarct ventricular septal defect (PIVSD) is a potentially
catastrophic complication of a myocardial infarction (MI) with
an incidence of 0.2% but a mortality of 94% if medically
managed.1 The PIVSD typically occurs between days 2 and 7
after a large MI, when the large necrotic zone weakens and
ruptures.2 The American College of Cardiology Foundation/
American Heart Association (ACCF/AHA) recommends early
surgery once the diagnosis is made.3 This defect can* Corresponding author.
E-mail address: ashish.pershad@bannerhealth.com (A. Pershad).
http://dx.doi.org/10.1016/j.ihj.2015.09.021
0019-4832/# 2015 Cardiological Society of India. Published by Elsevierdeteriorate further with time, as more myocardium becomes
afﬂicted or even with manipulation when attempts are made
to correct it. Current preference amongst surgeons is to allow
initial healing of the infarct for at least 2 weeks.4 This creates a
signiﬁcant selection bias in surgical series.
Fabricated 3D printed models using reconstructed comput-
ed tomography (CT) scans have become available to plan
complex pediatric and other structural heart surgeries.5
Although percutaneous PIVSD closure has been reported in
the literature, this is the ﬁrst case report where 3D printing and
modeling were used to guide closure. B.V. All rights reserved.
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A 57-year-old female presented late to an outside facility after
sustaining a non-ST-elevation myocardial infarction
(NSTEMI). She was treated with PCI of the left anterior
descending (LAD) and left circumﬂex coronary arteries. One
week later, she presented again for weakness and New York
Heart Association (NYHA) Class IV heart failure. A muscular
VSD was diagnosed on transthoracic echocardiography (TTE).
She was transferred to Banner University Medical Center-
Phoenix (BUMC-P) for management of this PIVSD. Due to her
deteriorating clinical condition and persistent state of cardio-
genic shock, the heart team made the decision that the patient
was a poor surgical candidate and would be better served with
an attempt at percutaneous closure.
To better characterize the defect, Cardiac CT and 3D
reconstruction of the data sets were performed, utilizing
Mimics (Materialise, Leuven, Belgium), a medical image
software suite. The resulting 3D computer model was
enhanced for 3D print viability through the use of secondary
postprocessing. The model was 3D printed on a zCorp 650
(3DSystems, Rock Hill, SC) in a gypsum-cyanoacrylate medi-
um. The 3D print was created at scale, providing an in vitro
model of the VSD to guide device selection and procedure
planning.
The procedure was performed in the hybrid operating room
14 days after her initial NSTEMI. The relative clinical stability
of the patient permitted this delay. Open surgical intervention
was planned in case of a procedural complication. Transeso-
phageal echocardiogram (TEE) measured the diameter of the
VSD at 12 mm (Fig. 1A and B). A 20 mm Amplatzer TM PIVSD
occluder (St Jude Medical, St Paul, MN) was selected to allow for
50% oversizing as recommended by operators in the US PIVSD
Registry (personal communication). Deployment of the VSD
occluder was performed in standard fashion as previously
described,1 with the following caveats:
1. The left ventricular (LV) to right ventricular (RV) crossing
was performed with a balloon-tipped catheter to allow for
passage through the largest defect rather than through a
smaller secondary defect.
2. The atrioventricular (AV) loop was created from the right
femoral artery to the right femoral vein because of the
anterior location of the defect in the septum. In other
instances, use of the jugular vein is preferred.
Postprocedural assessment included a LV angiogram and a
TEE to assess for device stability and residual shunt (Fig. 1C
and D). TEE demonstrated minimal shunt through the device.
The patient was monitored in the ICU for 24 h and discharged
home on postoperative day 4 on dual antiplatelet therapy and
guideline directed medical therapy for heart failure.
3. Discussion
PIVSD is not a discrete hole but rather ruptured septal tissue
with accompanying necrosis. The defect is more akin to a tear
and multiple serpiginous defects may develop. Risk factors forthe development of a PIVSD include advanced age, hyperten-
sion, inadequate collaterals, anterior MI, and ﬁbrinolysis.6
Early recognition of this complication remains paramount.
PIVSD is diagnosed clinically (on physical exam ﬁndings
typically present with a new harsh holosystolic murmur, thrill,
an S3 heart sound, and accentuated second heart sound), and
conﬁrmed with characteristic ﬁndings on TTE/TEE and cardiac
catheterization. Factors associated with in-hospital mortality
from a postinfarct VSD include advanced age, female sex,
NYHA class IV CHF, cardiogenic shock, renal failure, large
defect size, use of inotropic support, and nonrevascularized
myocardium.7
According to the ACCF/AHA guidelines, early surgical
closure of a post-MI VSD is a class I recommendation.3
However, surgical correction carries a mortality rate between
20 and 77%.8 The principles of surgical technique have evolved.
A dacron double patch with bioglue reinforcement is currently
the favored technique. No resection of the infarcted tissue is
performed with the goal being to not tense the ventricular
septum or the ventriculotomy with sutures.9 In addition to
high mortality rates and in spite of reﬁnements in surgical
techniques, the rate of residual shunting approaches 40%.
Muscular VSD closure methods have been well established
in the pediatric population. An extension of these techniques
had been proposed for PIVSD closure but the necrotic tissue
and nondiscrete nature of the defect were challenges. This
leads to the genesis of a dedicated PIVSD device. The
AmplatzerTM (St Jude Medical, St Paul, MN) postinfarct
muscular VSD device is very similar to the regular muscular
VSD device, albeit with two important differences. The length
of the waist is larger, at 10 millimeters (mm), and the discs are
10 mm larger than the connecting waist. The device is
available in sizes from 16 to 24 mm in 2 mm increments
and can be delivered through 9 to 10 French (Fr) long sheaths.
12 years ago, the results of the Multicenter US Registry with the
AmplatzerTM postinfarct muscular VSD device were published
demonstrating acceptable short-term and intermediate-term
outcomes with a 30-day mortality of 28%.10
Percutaneous closure success rates of PIVSDs are variable,
owing to either failure to implant the device or failure to close
the shunt even after proper device implantation.11 The key to
acute procedural success is good imaging of the defect. This
involves multimodality assessment with TTE, TEE with 3D
imaging, LV angiography, and a preprocedure CT or MR. In this
case, the added advantage was the use of 3D printing. This
permitted a trial of multiple devices with variable sizes and
assessment of their ﬁt in vitro. The ability to observe cardiac
structures in three dimensions with a printed model gives a
unique perspective to the operator, where the defect can be
visualized from both the left and right ventricles. This level of
detail enables the operator to test multiple occluders (ASD
occluder, muscular VSD occluder, and PIVSD occluder) in the
replicated model of the patient's heart before deploying it
in vivo. In this case, the operators would have chosen an ASD
occluder without 3D printing knowledge; however, the right-
sided disc of the 20 mm ASD occluder, although the same size
as the PIVSD occluder (30 mm), kept getting entangled in the
RV trabeculae in the 3D heart model. This did not permit full
coverage of the right ventricular side of the defect. Hence, the
operators chose to use the same sized-PIVSD occluder
Fig. 1 – (A) TEE demonstrating a PIVSD before implantation of a septal occluder device. (B) TEE demonstrating an intracardiac
shunt through a PIVSD with color Doppler, before implantation of a septal occluder device. (C) TEE demonstrating resolution
of a PIVSD after implantation of a septal occluder device. (D) TEE demonstrating resolution of an intracardiac shunt via color
Doppler, after implantation of a septal occluder device.
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(Fig. 2A–D). This schematic demonstrates how the occluder ﬁts
in a tight conﬁrmation. A ‘‘best ﬁt’’ device, as deﬁned by the
authors, is one that allows an occluder to safely transverse
through the PIVSD with minimal resistance (i.e., ease of
navigating through ventricular structures such as papillary
muscles and trabeculae) and allows for minimal sizing with
full coverage of the defect.
Another key to a successful procedure is the creation of an
AV loop. Snaring the wire in the pulmonary artery and
exteriorizing it through the jugular vein usually accomplishes
this. The AV loop serves as a stable rail to advance the deliverysheath, whereas a veno-venous loop using transeptal punc-
ture would be less suitable due to sheath angulation and
potential damage to the mitral valve apparatus.12 Rarely, if the
defect is anterior, femoral venous access may be preferred as
was performed in this case.
Cardiac CT and 3D printing are not without limitations. The
patient underwent cardiac CT while in heart failure with
tachycardia and restlessness causing motion artifact. This
caused a ‘‘stitch-artifact’’ in the reconstructed CT images. This
artifact was translated to the 3D printed model, although it
was not visualized on angiography (Supplemental Cine 1-2)
and TEE (Supplemental Cine 3-4) intraoperatively.
Fig. 2 – (A) 3D print model of the patient's heart demonstrating a PIVSD, viewed from the right ventricle. (B) 3D print model of
the patient's heart demonstrating a PIVSD with a 20 mm AmplatzerTM septal occluder (St Jude Medical, St Paul, MN), viewed
from the right ventricle. (C) 3D print model of the patient's heart demonstrating a PIVSD, viewed from the left ventricle. (D) 3D
print model of the patient's heart demonstrating a PIVSD, with a 20 mm AmplatzerTM septal occluder (St Jude Medical, St
Paul, MN), viewed from the left ventricle.
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Three-dimensional echocardiography and CT reconstruction
have been used previously to guide percutaneous treatment of
complex PIVSD. However, this is the ﬁrst case report utilizing
3D printing and modeling to guide size and choice of septal
occluder. In this case, a favorable outcome was obtained
because of the following reasons:
1. Adequate CT imaging and reconstruction
2. 3D printing to choose the appropriate device
3. Ability to wait 14 days after index infarction due to relative
clinical stability
4. No residual shunt at the conclusion of the procedure
PIVSDs are unique in each patient. The degree of necrosis,
location, shape, and number of defects are variable in each
patient. 3D printing has an invaluable role to play to customize
treatment on a case-by-case basis.
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